Ligand Pharmaceuticals Incorporated (LGND)

Jul 2, 2025 - LGND was delisted (reason: merged into PTHS)
113.30
+0.74 (0.66%)
Inactive · Last trade price on Jul 2, 2025
0.66%
Market Cap2.75B
Revenue (ttm)181.49M
Net Income (ttm)-132.62M
Shares Out 19.29M
EPS (ttm)-7.11
PE Ration/a
Forward PE136.54
Dividendn/a
Ex-Dividend Daten/a
Volume106,499
Open113.28
Previous Close112.56
Day's Range111.72 - 114.68
52-Week Range81.74 - 129.90
Beta0.74
AnalystsStrong Buy
Price Target144.71 (+27.72%)
Earnings DateAug 5, 2025

About LGND

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neurobla... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 18, 1992
Employees 68
Stock Exchange NASDAQ
Ticker Symbol LGND
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 8 analysts, the average rating for LGND stock is "Strong Buy." The 12-month stock price target is $144.71, which is an increase of 27.72% from the latest price.

Price Target
$144.71
(27.72% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance

Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million) an...

19 hours ago - GlobeNewsWire

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra's AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement  • Medtronic to i...

Other symbols: MDTOBIO
7 days ago - GlobeNewsWire

Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025

JUPITER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 202...

14 days ago - GlobeNewsWire

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially la...

4 weeks ago - GlobeNewsWire

Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 mill...

5 weeks ago - GlobeNewsWire

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics

Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company ...

5 weeks ago - GlobeNewsWire

Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward

I maintain my Buy rating on Ligand Pharmaceuticals due to its strong growth trajectory and diversified portfolio. Ligand offers investors exposure to dozens of therapies, reducing risk and increasing ...

6 weeks ago - Seeking Alpha

Ligand Announces 2025 Investor Day in New York City

JUPITER, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 9, 2025 at 1...

2 months ago - GlobeNewsWire

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that the company will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 20...

3 months ago - GlobeNewsWire

Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Melanie Herman – Executive Director-Investor Relations Todd Davis – Chie...

3 months ago - Seeking Alpha

Ligand Reports First Quarter 2025 Financial Results

First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Cr...

3 months ago - GlobeNewsWire

Ligand to Participate in May Investor Conferences

JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor c...

3 months ago - GlobeNewsWire

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2025 financial results before the opening of the ...

3 months ago - GlobeNewsWire

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI™ ZELSUVMI is an FDA-designated novel drug a...

4 months ago - GlobeNewsWire

Ligand to Participate in March Investor Conferences

JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza w...

5 months ago - GlobeNewsWire

Ligand Pharmaceuticals Incorporated (LGND) Q4 2024 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysi...

5 months ago - Seeking Alpha

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share 1 of $6...

5 months ago - GlobeNewsWire

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

Capital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors...

Other symbols: XOMA
5 months ago - GlobeNewsWire

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

JUPITER, Fla.--(BUSINESS WIRE)--Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025.

6 months ago - Business Wire

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

JUPITER, Fla.--(BUSINESS WIRE)--Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.

6 months ago - Business Wire

Looking Back On Ligand Pharmaceuticals

Today, I am circling back to Ligand Pharmaceuticals for the first time since late 2023. The stock has had a nice run in recent months and management has a solid game plan to grow revenues at north of ...

6 months ago - Seeking Alpha

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...

7 months ago - Seeking Alpha

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor and Analyst Day in Boston today. The event will feature presentations from Ligand CEO Todd Dav...

8 months ago - Business Wire

Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies

I continue to rate Ligand Pharmaceuticals stock as a "Buy" citing strong liquidity and a clean balance sheet. Its Q3 2024 earnings report beat on the top and bottom lines raising prior guidance, reinf...

9 months ago - Seeking Alpha

Ligand to Present at Stifel 2024 Healthcare Conference

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the...

9 months ago - Business Wire